Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00179803 · ClinicalTrials.gov registry record · Phase 2

Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors

A Phase 2 study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT00179803 is a Phase 2 study that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00179803, a Phase 2 study, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

The primary goal of this study is to determine if a stem cell transplant in patients with newly diagnosed high risk CNS tumors (glioblastoma multiforme \[GBM\], high grade astrocytoma, pineoblastoma, rhabdoid tumor, supratentorial primitive neuroectodermal tumor \[PNET\]) increases overall survival.

Interventions

  • PROCEDURE Stem Cell Transplant

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 1998-03
Est. Completion 2009-09
Phase Phase 2

What the Registry Record Tells You About NCT00179803

The ClinicalTrials.gov registry entry for NCT00179803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Stem Cell Transplant is the first listed.

NCT00179803 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00179803 about?

NCT00179803 is a clinical study titled "Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors". The primary goal of this study is to determine if a stem cell transplant in patients with newly diagnosed high risk CNS tumors (glioblastoma multiforme \[GBM\], high grade astrocytoma, pineoblastoma, rhabdoid tumor, supratentorial primitive neuroectodermal tumor \[PNET\]) increases overall survival.

What is the current status of trial NCT00179803?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 1998-03. Estimated completion is 2009-09.

What interventions are being tested in trial NCT00179803?

The interventions under investigation include: Stem Cell Transplant (PROCEDURE).

Who is sponsoring clinical trial NCT00179803?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.